Skip to main content

Table 5 Relation between thymus gland pathology of the studied patients and studied scores

From: Determinants of quality of life changes with plasmapheresis in patients with myasthenia gravis

  Thymus gland Test value P value Sig.
Total (52 patients) Normal
(31 patients)
Hyperplasia
(15 patients)
Thymoma
(6 patients)
Initial QMG score Mean ± SD 25.10 ± 3.48 28.87 ± 2.23 31.50 ± 1.52 15.770a 0.001 HS
Range 19-31 24-32 30-34
QMG score after 1 month Mean ± SD 16.32 ± 3.50 19.40 ± 3.50 25.67 ± 5.47 16.565a 0.001 HS
Range 11-23 11-24 15-30
QMG change Median (IQR) −34.62 (−43.48-−23.81) −31.25 (−35.71-−25) −15.08 (−19.35-−6.67) 6.488 0.039 S
Range −58.06-−13.64 −58.06-−8.33 −53.13-0
Test value 9.011 3.528 2.403    
P value 0.001 0.002 0.061
Initial QOL score Mean ± SD 45.71 ± 3.93 49.93 ± 4.22 52.83 ± 2.64 11.676a 0.001 HS
Range 39-54 44-57 49-57
QOL score after 1 month Mean ± SD 35.52 ± 6.47 41.33 ± 5.07 48.50 ± 6.83 13.166a 0.001 HS
Range 25-49 30-48 36-54
QOL change Median (IQR) −20 (−30.23-−10.64) −14.58 (−18.87 – −11.11) −5.52 (−11.54-0) 7.080 0.029 S
Range −50-−4.76 −41.51-−4.44 −33.33-8.16
Test value 7.360 2.517 1.415    
P value 0.001 0.021 0.216
  1. NS non-significant, S significant, HS highly significant, QOL quality of life, QMG quantitative myasthenia gravis, SD standard deviation
  2. aOne-way ANOVA